Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
Karyopharm Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 8, 2022
Karyopharm Therapeutics reported fiscal year 2021 executive compensation information on April 8, 2022.
In 2021, six executives at Karyopharm Therapeutics received on average a compensation package of $3.2M, a 2% decrease compared to previous year.
Average pay of disclosed executives at Karyopharm Therapeutics
Richard Paulson, Chief Executive Officer, received $8.4M in total. 43% of Paulson's compensation, or $3.6M, was in option awards. Paulson also received $300K in bonus, $436K in non-equity incentive plan, $468K in salary, $3.5M in stock awards, as well as $65K in other compensation.
Sharon Shacham, Chief Scientific Officer, received a compensation package of $3.1M, which decreased by 15% compared to previous year. 49% of the compensation package, or $1.5M, was in option awards.
Michael G. Kauffman, Chief Executive Officer, earned $3.1M in 2021, a 22% decrease compared to previous year.
Michael Mason, Chief Financial Officer, received $1.7M in 2021, which decreases by 23% compared to 2020.
Jatin Shah, Chief Medical Officer, earned $1.6M in 2021.
Ran Frenkel, Executive Vice President, Chief Development Officer, received $1.6M in 2021.
Related executives
Richard Paulson
Karyopharm Therapeutics
Chief Executive Officer
Michael Kauffman
Karyopharm Therapeutics
Chief Executive Officer
Michael Mason
Karyopharm Therapeutics
Chief Financial Officer
Ran Frenkel
Karyopharm Therapeutics
Executive Vice President, Chief Development Officer
Sharon Shacham
Karyopharm Therapeutics
Chief Scientific Officer
Jatin Shah
Karyopharm Therapeutics
Chief Medical Officer
You may also like
Source: SEC filing on April 8, 2022.